Off-label prescription: Practice and problems | Revista Portuguesa de Cardiologia (English edition)

array:25 ["pii" => "S2174204913001803" "issn" => "21742049" "doi" => "10.1016/j.repce.2013.01.016" "estado" => "S300" "fechaPublicacion" => "2013-09-01" "aid" => "302" "copyright" => "Sociedade Portuguesa de Cardiologia" "copyrightAnyo" => "2012" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "ssu" "cita" => "Rev Port Cardiol. 2013;32:681-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5179 "formatos" => array:3 [ "EPUB" => 160 "HTML" => 4062 "PDF" => 957 ] ] "Traduccion" => array:1 [ "pt" => array:20 [ "pii" => "S0870255113001315" "issn" => "08702551" "doi" => "10.1016/j.repc.2013.01.006" "estado" => "S300" "fechaPublicacion" => "2013-09-01" "aid" => "302" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "ssu" "cita" => "Rev Port Cardiol. 2013;32:681-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 8750 "formatos" => array:3 [ "EPUB" => 172 "HTML" => 7059 "PDF" => 1519 ] ] "pt" => array:12 [ "idiomaDefecto" => true "cabecera" => "Artigo de revisão" "titulo" => "A prescrição fora das indicações aprovadas (off-label): prática e problemas" "tienePdf" => "pt" "tieneTextoCompleto" => "pt" "tieneResumen" => array:2 [ 0 => "pt" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "681" "paginaFinal" => "686" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Off-label prescription: Practice and problems" ] ] "contieneResumen" => array:2 [ "pt" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "pt" => true ] "contienePdf" => array:1 [ "pt" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "António Vaz Carneiro, João Costa" "autores" => array:2 [ 0 => array:2 [ "nombre" => "António" "apellidos" => "Vaz Carneiro" ] 1 => array:2 [ "nombre" => "João" "apellidos" => "Costa" ] ] ] ] ] "idiomaDefecto" => "pt" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2174204913001803" "doi" => "10.1016/j.repce.2013.01.016" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204913001803?idApp=UINPBA00004E" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255113001315?idApp=UINPBA00004E" "url" => "/08702551/0000003200000009/v1_201309260109/S0870255113001315/v1_201309260109/pt/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2174204913002468" "issn" => "21742049" "doi" => "10.1016/j.repce.2013.02.016" "estado" => "S300" "fechaPublicacion" => "2013-09-01" "aid" => "313" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "ssu" "cita" => "Rev Port Cardiol. 2013;32:687-700" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3948 "formatos" => array:3 [ "EPUB" => 184 "HTML" => 3194 "PDF" => 570 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "Review article" "titulo" => "Heart rate variability in myocardial infarction patients: Effects of exercise training" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "687" "paginaFinal" => "700" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Variabilidade da frequência cardíaca em pacientes após enfarte do miocárdio: efeitos do exercício físico regular" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Nórton Luís Oliveira, Fernando Ribeiro, Alberto Jorge Alves, Madalena Teixeira, Fátima Miranda, José Oliveira" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Nórton Luís" "apellidos" => "Oliveira" ] 1 => array:2 [ "nombre" => "Fernando" "apellidos" => "Ribeiro" ] 2 => array:2 [ "nombre" => "Alberto Jorge" "apellidos" => "Alves" ] 3 => array:2 [ "nombre" => "Madalena" "apellidos" => "Teixeira" ] 4 => array:2 [ "nombre" => "Fátima" "apellidos" => "Miranda" ] 5 => array:2 [ "nombre" => "José" "apellidos" => "Oliveira" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204913002468?idApp=UINPBA00004E" "url" => "/21742049/0000003200000009/v1_201312060118/S2174204913002468/v1_201312060118/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S2174204913001785" "issn" => "21742049" "doi" => "10.1016/j.repce.2013.10.014" "estado" => "S300" "fechaPublicacion" => "2013-09-01" "aid" => "271" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Cardiol. 2013;32:673-80" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3907 "formatos" => array:3 [ "EPUB" => 180 "HTML" => 2987 "PDF" => 740 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Original Article" "titulo" => "Acute myocardial infarction complicated by cardiogenic shock: What changed over a 10-year time span" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "673" "paginaFinal" => "680" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Choque cardiogénico no enfarte agudo do miocárdio: o que mudou nos últimos 10 anos?" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1739 "Ancho" => 1570 "Tamanyo" => 108976 ] ] "descripcion" => array:1 [ "en" => "Kaplan-Meier analysis of all-cause mortality at six months." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Hélder Dores, Jorge Ferreira, Francisco Costa, Carlos Aguiar, Gonçalo Cardoso, Rui Teles, Pedro de Araújo Gonçalves, Luís Raposo, Marisa Trabulo, Manuel de Sousa Almeida, José Pedro Neves, Miguel Mendes" "autores" => array:12 [ 0 => array:2 [ "nombre" => "Hélder" "apellidos" => "Dores" ] 1 => array:2 [ "nombre" => "Jorge" "apellidos" => "Ferreira" ] 2 => array:2 [ "nombre" => "Francisco" "apellidos" => "Costa" ] 3 => array:2 [ "nombre" => "Carlos" "apellidos" => "Aguiar" ] 4 => array:2 [ "nombre" => "Gonçalo" "apellidos" => "Cardoso" ] 5 => array:2 [ "nombre" => "Rui" "apellidos" => "Teles" ] 6 => array:2 [ "nombre" => "Pedro de Araújo" "apellidos" => "Gonçalves" ] 7 => array:2 [ "nombre" => "Luís" "apellidos" => "Raposo" ] 8 => array:2 [ "nombre" => "Marisa" "apellidos" => "Trabulo" ] 9 => array:2 [ "nombre" => "Manuel" "apellidos" => "de Sousa Almeida" ] 10 => array:2 [ "nombre" => "José Pedro" "apellidos" => "Neves" ] 11 => array:2 [ "nombre" => "Miguel" "apellidos" => "Mendes" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "pt" => array:9 [ "pii" => "S0870255113000711" "doi" => "10.1016/j.repc.2012.12.013" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255113000711?idApp=UINPBA00004E" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204913001785?idApp=UINPBA00004E" "url" => "/21742049/0000003200000009/v1_201312060118/S2174204913001785/v1_201312060118/en/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "Review article" "titulo" => "Off-label prescription: Practice and problems" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "681" "paginaFinal" => "686" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "António Vaz Carneiro, João Costa" "autores" => array:2 [ 0 => array:4 [ "nombre" => "António" "apellidos" => "Vaz Carneiro" "email" => array:1 [ 0 => "avc@fm.ul.pt" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "¿" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "João" "apellidos" => "Costa" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "A prescrição fora das indicações aprovadas (off-label): prática e problemas" ] ] "textoCompleto" => "IntroductionA drug is only used in clinical practice after a complex process of research and development that lasts on average 12-15 years, of which marketing authorization is the penultimate step. This is granted by the European Medicines Agency for all European countries. For such authorization to be given, evidence must be provided of efficacy and safety through submission of the results of phase 3 randomized controlled trials (RCTs), in which the new molecule is compared with placebo or an active comparator.In most cases, the last step in the process is the adoption of the drug by national authorities for outpatient and/or hospital use. It is this step that, with rare exceptions, makes the drug available to patients. This decision is taken when the national authority (Infarmed in Portugal) makes a positive appraisal of the new drug's health and/or economic benefits (the latter through economic evaluation studies), compared to the alternative reference therapy used in clinical indications for the disease in question. Only if the new drug constitutes a therapeutic innovation – by filling a therapeutic gap when compared with placebo, no treatment or best supportive care – will it be adopted. A substance is not necessarily a therapeutic innovation simply because it is new.<a class="elsevierStyleCrossRef" href="#bib0005">1</a>Central to this process is the definition of indications for the drug in question. These indications are crucial, because drugs are approved (or not) on the basis of their net clinical benefit for specific and well-defined diseases and – importantly – only for these.Once the drug is granted marketing authorization, the manufacturer can only market it for the approved indication(s); it is illegal to promote, directly or indirectly, or even to suggest, its use for other diseases or other types of patients (although this does happen<a class="elsevierStyleCrossRef" href="#bib0010">2</a>). Pharmaceutical companies can add new indications to those already approved, but they rarely do, because the clinical trials required are lengthy and expensive and there is little incentive to conduct them, since the drug is already on the market. More common are extensions to the approved indications, such as to other age-groups or to different patient subtypes. Generic drug manufacturers are likewise reluctant to conduct the RCTs needed for new approvals, for the same financial reasons.Once the drug is available for use in tens or hundreds of thousands of patients, physicians may realize that some medications can be effective in diseases for which they were not approved, i.e., no studies have been presented to the regulatory authorities, and therefore they are not formally approved for those indications. Convinced of the benefits for their patients, some physicians prescribe them for unapproved indications – off-label prescription.Off-label prescription is thus defined as prescription for an indication, disease, or patient outside the approved indications, or for populations that have not been studied (such as pediatric patients), or using methods of administration or dosages that have not been approved.<a class="elsevierStyleCrossRef" href="#bib0015">3</a> The rationale for off-label prescription is that the official agencies do not regulate the practice of medicine, and that physicians are free to decide what they consider best for their patients.There are two types of off-label prescription:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005">•the use of a drug that is indicated for a particular disease in a completely different condition, such as anti-epileptic agents for neuropathic pain;</li><li class="elsevierStyleListItem" id="lsti0010">•the use of a drug within its indications, but outside the approved specifications, such as sildenafil, approved for erectile dysfunction but used by patients without this condition in order to enhance sexual performance.</li></ul>The spectrum of off-label use includes guideline-recommended practice (aspirin in diabetes for prophylaxis against cardiovascular disease), last-resort therapy (tacrolimus for autoimmune diseases, in addition to transplantation), and first-line therapy (gabapentin for painful diabetic neuropathy).Certain types of off-label prescription are of particular concern and require careful scrutiny<a class="elsevierStyleCrossRef" href="#bib0020">4</a>:<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0015">•The off-label use of recently introduced drugs is a major problem, since not only will there be virtually no evidence of their benefit, but safety data from pharmacovigilance will also be scarce, obviously complicating their use.</li><li class="elsevierStyleListItem" id="lsti0020">•Novel off-label use – one that is different from usual clinical practice – has similar problems of lack of data on efficacy and especially on safety, even if the drug itself has been on the market for more than 3-5 years.</li><li class="elsevierStyleListItem" id="lsti0025">•When any drug with known serious or frequent adverse effects is prescribed off-label, this use merits close attention owing to concerns for patient safety.</li><li class="elsevierStyleListItem" id="lsti0030">•Finally, off-label prescription of high-cost drugs raises its own questions, since the financial penalty involved demands particular practical reflection.</li></ul>In this paper we discuss some formal and practical aspects of off-label prescription, including its prevalence, advantages and disadvantages, and examine the nature of the evidence supporting its use.The prevalence of off-label prescriptionSo long as drugs prescribed off-label are safe, well tolerated and inexpensive, the practice does not usually lead to major problems. However, as stated above, problems arise with high-cost drugs for specific diseases, a well-known example of which is new biological drugs for the treatment of cancer; in some studies, off-label administration of these drugs reaches 75%.<a class="elsevierStyleCrossRef" href="#bib0025">5</a>In any event, whether for outpatient or in-hospital use, off-label prescription occurs for almost all drug classes, with a particularly high prevalence for certain drugs (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>In cardiology, a typical example of off-label prescription is the use of new anticoagulants – dabigatran, rivaroxaban, apixaban – in situations in which warfarin is the first-line drug. A recent analysis examined other off-label uses of cardiological drugs, including thrombin and factor Xa inhibitors<a class="elsevierStyleCrossRef" href="#bib0030">6</a>; other common examples are the use of aspirin for cardiological prevention in diabetic patients and of beta-blockers for essential tremor.For some drugs, of course, good evidence is available for their use in particular conditions (such as beta-blockers for essential tremor, as mentioned above<a class="elsevierStyleCrossRef" href="#bib0035">7</a>) but no formal indication has been approved; it should be borne in mind that only the holder of the marketing authorization has the legal right to alter or add to a drug's indications, and that the authorities cannot do so.One well-publicized case of the existence of evidence for an unapproved indication is of bevacizumab (Avastin®) for age-related macular degeneration, for which the only drug with formal indication is ranibizumab (Lucentis®). A non-inferiority clinical trial comparing the two, the CATT trial,<a class="elsevierStyleCrossRef" href="#bib0040">8</a> concluded that ranibizumab and bevacizumab had equivalent effects on visual acuity at one year and that differences in rates of serious adverse events require further study.Another example of off-label prescription is the use of recombinant factor VIIa.<a class="elsevierStyleCrossRef" href="#bib0045">9</a> Initially approved only for the treatment of hemophilia, especially in patients who have developed factor VII inhibitors, recombinant factor VIIa is used as a hemostatic agent in cardiac surgery, trauma and intracranial hemorrhage, to the point that prescription for approved indications accounts for only 3% of cases.<a class="elsevierStyleCrossRef" href="#bib0050">10</a>The prevalence of off-label prescription has not received the attention that it warrants. Various numbers appear in the literature, ranging from 20%<a class="elsevierStyleCrossRef" href="#bib0055">11</a> to 50% (Pharmaceutical Executive 2012) of prescriptions in the US, 60% in some Australian hospitals (Discussion Paper Working Group of NSW TAG, 2003), 30% in outpatients in the UK (NICE 2012) and 23% in Europe.<a class="elsevierStyleCrossRef" href="#bib0060">12</a> The most frequently cited study,<a class="elsevierStyleCrossRef" href="#bib0065">13</a> based on a US survey of outpatient prescriptions, reports an overall rate of 21% of off-label prescription, rising to 46% of cardiac medications (excluding lipid-lowering and antihypertensive medications) and of anticonvulsants. Gabapentin had the highest proportion of off-label prescription (83%), followed by amitriptyline (81%). In most cases (73%) there was no evidence to back up the use of these drugs outside their approved indications.To summarize, off-label prescription is very common, and the drug classes involved are generally the more complex ones.The advantages of off-label prescriptionOff-label prescription may occur for a variety of different reasons<a class="elsevierStyleCrossRef" href="#bib0030">6</a>:<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0035">1.a class effect, by which drugs of the same class are presumed have similar effects in a particular disease (for example, the use of a statin for primary prevention that has only been studied for secondary prevention);</li><li class="elsevierStyleListItem" id="lsti0040">2.extension of therapies approved for severe clinical situations to milder forms, such as the use of spironolactone, approved for patients in NYHA classes III and IV, for patients in classes I and II<a class="elsevierStyleCrossRefs" href="#bib0070">14,15</a>;</li><li class="elsevierStyleListItem" id="lsti0045">3.extension to related conditions (use of the antiasthmatic montelukast for chronic obstructive pulmonary disease);</li><li class="elsevierStyleListItem" id="lsti0050">4.expansion to distinct conditions sharing a physiological link (use of the antidiabetic drug metformin to treat polycystic ovarian syndrome); and</li><li class="elsevierStyleListItem" id="lsti0055">5.extension to conditions whose symptoms overlap with those of an approved indication, in the belief that the off-label treatment will be equally effective (gabapentin for non-neuropathic pain syndromes).</li></ul>Besides these justifications for off-label prescription, there are other arguments in its favor<a class="elsevierStyleCrossRefs" href="#bib0030">6,11</a>: it enables new indications to be discovered, particularly when approved treatments have failed; it can dispense with the lengthy and costly drug approval process via official agencies, offering earlier access to drugs and adoption of new practices based on emerging evidence (and thereby enabling physicians to accumulate evidence prior to official approval); and experimentation with new drugs can be justified for many less common diseases for which there are no effective approved treatments.Furthermore, there are some circumstances in which there is no alternative to off-label prescription. The most obvious example of this is pediatrics. Since very few clinical trials are performed in children, most drugs used in pediatric populations do not have approved indications. Another example is in certain rare diseases that also lack approved treatments due to the impossibility of carrying out effective clinical trials; here also the only possible treatment may be with drugs approved for other conditions. But off-label prescription for common conditions also occurs in clinical practice; for example, the use of beta-blockers in congestive heart failure began before there were clinical trials to support this indication.Problems with off-label prescriptionGiven the complex and painstaking process of approval and introduction that new drugs must go through, which is intended to ensure both their efficacy and safety, any use outside the indications for which they were evaluated naturally raises important questions.Prescription of a drug outside its approved indications will increase the individual physician's civil and criminal responsibility. It has been suggested that physicians should in some cases be obliged to provide patients with information on the risks of off-label prescription and to obtain their consent – a similar process to the informed consent process.<a class="elsevierStyleCrossRef" href="#bib0055">11</a> In times of economic constraints other considerations come into play, since health authorities – whether local (hospitals and family health centers), regional or national – are under increasing pressure to audit and monitor drug prescriptions and to take measures, individually and collectively, to rationalize their use.Unlike physicians, the drug manufacturers have little legal liability with regard to off-label prescription, since they can only be held responsible for problems that arise when their product is used within its approved indications. Furthermore, off-label prescription may in fact discourage the pharmaceutical industry from conducting clinical trials for new or different indications (thereby reducing public confidence in the drug evaluation process), encourage ever wider use in unstudied populations such as children and the elderly, and, when the drugs in question are expensive, increase health care costs.One of the main concerns with off-label prescription is the lack of effective pharmacovigilance due to a low level of reporting, which may obscure safety issues. It should be recalled that drugs with a good safety profile for a specific use, prescribed for the studied population and with the approved indications, may not be safe with unapproved use and/or in unstudied patient groups.An example of this is the CATT trial referred to above, which compared ranibizumab (the approved drug) and bevacizumab (unapproved) for the treatment of age-related macular degeneration, and which revealed differences in serious adverse effects between the two.<a class="elsevierStyleCrossRefs" href="#bib0040">8,16</a> Although the differences did not permit firm conclusions to be drawn, the authors stated that further studies were required to assess the safety of the two drugs, particularly bevacizumab. This led to a recent systematic review directly comparing three RCTs, including the CATT trial, with a total of 1333 patients, that assessed the safety of off-label use of bevacizumab vs. ranibizumab for the same indications.<a class="elsevierStyleCrossRef" href="#bib0085">17</a> The results showed that bevacizumab has a significantly higher rate of ocular adverse effects (risk ratio [RR] 2.8; 95% confidence interval [CI] 1.2-6.5) and serious infections and gastrointestinal disorders (RR 1.3; 95% CI 1.0-1.7). In indirect comparisons with a variety of controls (5 RCTs, 4054 patients), and based on the two-year results of three landmark trials, the risk of ocular adverse effects was higher for bevacizumab (RR 3.1; 95% CI 1.1-8.9), even though the absolute baseline risk for these patients was low (2.1%). A significant increase in nonocular hemorrhage was observed with ranibizumab (RR 1.7; 95% CI 1.1-2.7), while no difference was detected in the incidence of arterial thromboembolic events.As well as providing a better characterization of the safety of off-label bevacizumab, this review included several studies and was thus better able to find differences between the drugs, thereby partly overcoming the limitations of individual trials to identify safety issues. The consequence in this case has been a change in the Summary of Product Characteristics for bevacizumab, which now include the risk of ocular adverse reactions following unapproved intravitreal use of bevacizumab under the heading “Special warnings and precautions for use” (<a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf</a>, accessed October 31, 2012).Besides the potential safety issues with off-label bevacizumab, the results of the CATT trial are a classic example of the limited ability of clinical trials to characterize the safety and tolerability of drug therapies, particularly when adverse events are uncommon (though serious) and/or occur late, due to the limited number of patients and duration of the trial. A well-known recent example was the cardiovascular risk of cyclooxygenase inhibitors.<a class="elsevierStyleCrossRef" href="#bib0090">18</a> Most clinical trials now have open extensions, during which patients are treated for a specific period (usually until the new drug is licensed). The main aim of such extensions is to evaluate safety and tolerability.The evidence for off-label prescriptionAs stated above, the evidence produced by the original investigation is mainly intended for the regulatory approval process of new drugs with a view to their introduction to the market. However, there may be evidence that could serve as the basis for the drug to be used outside its approved indications. In this case, the question is whether the physician can justify off-label prescription if there is good evidence to support the practice.In our opinion, routine off-label use of drugs may be justified if there is high-quality (real-world) evidence that they are effective and safe, and that their overall risk/benefit ratio is acceptable for a specific context (such as data on long-term use in chronic diseases).<a class="elsevierStyleCrossRef" href="#bib0015">3</a>One proposed classification of evidence that could support off-label prescription divides it into supported evidence (with a moderate to high level of certainty of net health benefits), suppositional evidence (a low level of certainty), and investigational evidence (unknown level).<a class="elsevierStyleCrossRef" href="#bib0020">4</a>One of the more complicated problems with evidence that may support off-label prescription is that it can be presented in a variety of ways, some of which lack rigor. A recent study of compendia of indications for off-label oncology treatments<a class="elsevierStyleCrossRef" href="#bib0095">19</a> found that they cited little of the available evidence, often neither the most recent nor that of highest methodological quality, and were analyzed on a completely random basis. For the 14 off-label indications studied, the compendia differed in the indications included and whether and how they recommended particular agents for particular types of cancer.To summarize, off-label use of a drug may be justified if there is high-quality evidence to support such use, bearing in mind that the results may differ markedly from those obtained when the drug is used within its approved indications.ConclusionsOff-label prescription is an inescapable aspect of modern health care systems.In this paper we set out to examine the need to obtain evidence to support the use of drugs outside their approved indications and thereby to promote rational and evidence-based prescription. Such use should always be an exception, to reduce inappropriate use and to ensure patients’ safety.When prescribing, the physician should pay particular attention to the adverse effects of off-label use and whenever possible should obtain supporting evidence.Although we recognize that in certain areas, such as pediatrics and oncology, off-label prescription is inevitable, we argue that it should always be an exception and should be supported by high-quality evidence that the physician must be able to explain.Ethical disclosuresProtection of human and animal subjectsThe authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).Confidentiality of dataThe authors declare that they have followed the protocols of their work center on the publication of patient data and that all the patients included in the study received sufficient information and gave their written informed consent to participate in the study.Right to privacy and informed consentThe authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.Conflicts of interestThe authors have no conflicts of interest to declare." "textoCompletoSecciones" => array:1 [ "secciones" => array:9 [ 0 => array:2 [ "identificador" => "xres296957" "titulo" => "Abstract" ] 1 => array:2 [ "identificador" => "xpalclavsec280622" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres296956" "titulo" => "Resumo" ] 3 => array:2 [ "identificador" => "xpalclavsec280621" "titulo" => "Palavras-chave" ] 4 => array:3 [ "identificador" => "sec0005" "titulo" => "Introduction" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0010" "titulo" => "The prevalence of off-label prescription" ] 1 => array:2 [ "identificador" => "sec0015" "titulo" => "The advantages of off-label prescription" ] 2 => array:2 [ "identificador" => "sec0020" "titulo" => "Problems with off-label prescription" ] 3 => array:2 [ "identificador" => "sec0025" "titulo" => "The evidence for off-label prescription" ] ] ] 5 => array:2 [ "identificador" => "sec0030" "titulo" => "Conclusions" ] 6 => array:3 [ "identificador" => "sec0035" "titulo" => "Ethical disclosures" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0040" "titulo" => "Protection of human and animal subjects" ] 1 => array:2 [ "identificador" => "sec0045" "titulo" => "Confidentiality of data" ] 2 => array:2 [ "identificador" => "sec0050" "titulo" => "Right to privacy and informed consent" ] ] ] 7 => array:2 [ "identificador" => "sec0055" "titulo" => "Conflicts of interest" ] 8 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2012-12-22" "fechaAceptado" => "2013-01-19" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec280622" "palabras" => array:4 [ 0 => "Off-label prescription" 1 => "Drug efficacy and safety" 2 => "Drug indications" 3 => "Drug regulatory approval processes" ] ] ] "pt" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palavras-chave" "identificador" => "xpalclavsec280621" "palabras" => array:4 [ 0 => "Prescrição off-label" 1 => "Eficácia e segurança de medicamentos" 2 => "Indicações medicamentosas" 3 => "Processos regulamentares de aprovação de medicamentos" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "Approval of a drug for clinical use requires production of data on efficacy and safety through submission of results from randomized controlled trials (RCTs), in which the new molecule is usually compared with placebo (or an active comparator) for a set of outcomes that will serve as the basis for the drug's indications. These indications are crucial, because drugs are approved on the basis of their net clinical benefit for specific and well-defined diseases and–importantly–only for these. Once the drug is available for use in tens or hundreds of thousands of patients, physicians may realize that some medications can be effective in diseases for which they were not approved, i.e., no studies have been presented to the regulatory authorities, and therefore they are not formally approved for those indications. Convinced of the benefits for their patients, some physicians prescribe them for unapproved indications–off-label prescription." ] "pt" => array:2 [ "titulo" => "Resumo" "resumen" => "O processo de aprovação de medicamentos para uso clínico implica a produção de provas de eficácia e segurança através da submissão de resultados de ensaios clínicos, em que a nova molécula é comparada habitualmente ao placebo (ou a um comparador ativo) para um conjunto de resultados nos quais se baseará a determinação das indicações. As indicações são absolutamente cruciais, porque os fármacos são aprovados segundo o perfil de benefício/risco que apresentam para tratamento de patologias específicas, bem definidas e - um aspeto muito importante - apenas para estas. Uma vez estando o medicamento disponível para ser utilizado em dezenas ou centenas de milhares de doentes, acontece por vezes que, no decurso do seu uso regular e rotineiro, chega ao conhecimento dos médicos que certas moléculas podem ser eficazes em situações para as quais não foram aprovadas, isto é, em que não foram apresentados estudos de suporte às autoridades regulamentares e que portanto não estão legalmente aprovadas para essas indicações. Convictos dos benefícios para os seus doentes, alguns médicos vão receitar medicamentos para indicações não aprovadas - a chamada prescrição off-label.Neste artigo discute-se a prevalência da prescrição off-label, assim como as suas vantagens e inconvenientes." ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Vaz Carneiro A, Costa J. A prescrição fora das indicações aprovadas (off-label): prática e problemas. Rev Port Cardiol. 2013;32:681–686." ] ] "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "ADHD: attention deficit/hyperactivity disorder." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Type of drug \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Examples of off-label use \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Anti-seizure drugs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Migraines, depression, nerve pain \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Antipsychotics \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Alzheimer's disease, autism, dementia, ADHD \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Antidepressants \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Chronic pain, ADHD, bipolar disorder \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Antihistamines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Colds, asthma, ear infection symptoms, as sleep aids \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Antibiotics \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Viral infections (colds and influenza) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Anxiety drugs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">To ease “normal” life stresses, as sleep aids \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Proton pump inhibitors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Occasional heartburn, indigestion, irritable bowel \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Beta-blockers \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Migraine, heart rhythm disorders, anxiety \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Drugs to treat ADHD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">For people not diagnosed with ADHD, to enhance alertness and concentration \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Insomnia medicines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">For people with infrequent insomnia, insomnia associated with depression, anxiety \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Narcotic pain relievers \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">For people with only mild, infrequent pain \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Specific drugs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Examples of off-label use \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Aripiprazole (antipsychotic) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dementia, Alzheimer's disease \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Albuterol (for asthma) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Bad coughs \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lamictal (antiepileptic, anti-seizure) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Depression, bipolar disorder, mood stabilization \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tiagabine (antiepileptic) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Depression, mood stabilization \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gabapentin (antiepileptic) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Depression, nerve pain, migraines \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Topiramate (antiepileptic) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Migraines, bipolar disorder, depression, nerve pain \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Risperidone (antipsychotic) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Alzheimer's disease, dementia, eating disorders \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lidoderm (skin patch for shingles) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lower back pain, sore muscles, tennis elbow \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Trazodone (antidepressant) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">As a sleep aid and for insomnia \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Propranolol (high blood pressure and heart disease) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Performance anxiety \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Modafinil (for excessive sleepiness) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">To enhance wakefulness and alertness \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sildenafil, vardenafil, tadalafil (erectile dysfunction) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">To enhance sexual performance in people not diagnosed with erectile dysfunction \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Bevacizumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Wet age-related macular degeneration \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab433149.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Drugs commonly prescribed off-label (Consumer Reports Best Buy Drugs, www.CRBestBuyDrugs.org, accessed August 2012).<a class="elsevierStyleCrossRef" href="#bib0100">20</a>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:20 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Valor terapêutico acrescentado" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "C. Ribeiro" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Port Clin Geral" "fecha" => "2008" "volumen" => "24" "paginaInicial" => "723" "paginaFinal" => "728" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A hemorrhage of off-label use" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J. Avorn" 1 => "A. Kesselheim" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/0003-4819-154-8-201104190-00010" "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med" "fecha" => "2011" "volumen" => "154" "paginaInicial" => "566" "paginaFinal" => "567" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21502655" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Off-label use of medicines: Consensus recommendations for evaluating appropriateness" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Gazarian" 1 => "M. Kelly" 2 => "J.R. McPhee" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Med J Aust" "fecha" => "2006" "volumen" => "185" "paginaInicial" => "544" "paginaFinal" => "548" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17115966" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Going off-label without venturing off-course: Evidence and ethical off-label prescribing" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "E.A. Largent" 1 => "F.G. Miller" 2 => "S.D. Pearson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archinternmed.2009.314" "Revista" => array:6 [ "tituloSerie" => "Arch Intern Med" "fecha" => "2009" "volumen" => "169" "paginaInicial" => "1745" "paginaFinal" => "1747" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19858430" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of off-label use of oncology drugs on pharmaceutical costs: The rituximab experience" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D. Kocs" 1 => "A.M. Fendrick" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Manag Care" "fecha" => "2003" "volumen" => "9" "paginaInicial" => "393" "paginaFinal" => "400" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12744301" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Regulating off-label drug use--rethinking the role of the FDA" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "R.S. Stafford" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMp0802107" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2008" "volumen" => "358" "paginaInicial" => "1427" "paginaFinal" => "1429" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18385495" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Essential tremor" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.J. Ferreira" 1 => "S. Sampaio" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Clin Evidence" "fecha" => "2007" "paginaInicial" => "1206" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ranibizumab and bevacizumab for neovascular age-related macular degeneration" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "D.F. Martin" 1 => "M.G. Maguire" 2 => "G.S. Ying" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1102673" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2011" "volumen" => "364" "paginaInicial" => "1897" "paginaFinal" => "1908" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21526923" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Off-label use of recombinant factor VIIa in U.S. hospitals: Analysis of hospital records" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.C. Logan" 1 => "V. Yank" 2 => "R.S. Stafford" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/0003-4819-154-8-201104190-00002" "Revista" => array:6 [ "tituloSerie" => "Ann Int Med" "fecha" => "2011" "volumen" => "154" "paginaInicial" => "516" "paginaFinal" => "522" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21502649" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systematic review: Benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "V. Yank" 1 => "C.V. Tuohy" 2 => "A.C. Logan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/0003-4819-154-8-201104190-00004" "Revista" => array:6 [ "tituloSerie" => "Ann Int Med" "fecha" => "2011" "volumen" => "154" "paginaInicial" => "529" "paginaFinal" => "540" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21502651" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Controlling off-label medication use" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M.R. Gillick" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Int Med" "fecha" => "2009" "volumen" => "150" "paginaInicial" => "344" "paginaFinal" => "347" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19221367" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prescrição de medicamentos off-label" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A. Escoval" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Port Farmacoter" "fecha" => "2011" "volumen" => "3" "paginaInicial" => "169" "paginaFinal" => "171" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Off-label prescribing among office-based physicians" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D.C. Radley" 1 => "S.N. Finkelstein" 2 => "R.S. Stafford" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archinte.166.9.1021" "Revista" => array:6 [ "tituloSerie" => "Arch Intern Med" "fecha" => "2006" "volumen" => "166" "paginaInicial" => "1021" "paginaFinal" => "1026" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16682577" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "D.N. Juurlink" 1 => "M.M. Mamdani" 2 => "D.S. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa040135" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2004" "volumen" => "351" "paginaInicial" => "543" "paginaFinal" => "551" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15295047" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of heart failure with spironolactone-trial and tribulations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.J. McMurray" 1 => "E. O’Meara" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMp048144" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2004" "volumen" => "351" "paginaInicial" => "526" "paginaFinal" => "528" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15295043" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bevacizumab versus ranibizumab for AMD" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "P.J. Rosenfeld" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMe1103334" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2011" "volumen" => "364" "paginaInicial" => "1966" "paginaFinal" => "1967" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21526924" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A safety review and meta-analyses of bevacizumab and ranibizumab: Off-label versus goldstandard" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C. Schmucker" 1 => "C. Ehlken" 2 => "H.T. Agostini" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0042701" "Revista" => array:5 [ "tituloSerie" => "PLoS One" "fecha" => "2012" "volumen" => "7" "paginaInicial" => "e42701" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22880086" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical trials in the wake of Vioxx: Requiring statistically extreme evidence of benefit to ensure the safety of new drugs" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M.D. Roth-Cline" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/CIRCULATIONAHA.105.604512" "Revista" => array:6 [ "tituloSerie" => "Circulation" "fecha" => "2006" "volumen" => "113" "paginaInicial" => "2253" "paginaFinal" => "2259" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16684875" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systematic review: Reliability of compendia methods for off-label oncology indications" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "A.P. Abernethy" 1 => "G. Raman" 2 => "E.M. Balk" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Int Med" "fecha" => "2009" "volumen" => "150" "paginaInicial" => "336" "paginaFinal" => "343" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19221366" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Consumer Reports Best Buy Drugs [accessed 10 August 2012]. Available from: <a id="intr0020" class="elsevierStyleInterRef" href="http://www.crbestbuydrugs.org/">www.CRBestBuyDrugs.org</a>." ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21742049/0000003200000009/v1_201312060118/S2174204913001803/v1_201312060118/en/main.assets" "Apartado" => array:4 [ "identificador" => "21467" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Evidenced-Based Cardiology" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21742049/0000003200000009/v1_201312060118/S2174204913001803/v1_201312060118/en/main.pdf?idApp=UINPBA00004E&text.app=https://revportcardiol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204913001803?idApp=UINPBA00004E"]

Statistics

Review article

Off-label prescription: Practice and problems

A prescrição fora das indicações aprovadas (off-label): prática e problemas

António Vaz Carneiro

Corresponding author

avc@fm.ul.pt

Corresponding author.

, João Costa

Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal

Read

9789

Times
was read the article

2284

Total PDF

7505

Total HTML

Share statistics

 array:25 [
  "pii" => "S2174204913001803"
  "issn" => "21742049"
  "doi" => "10.1016/j.repce.2013.01.016"
  "estado" => "S300"
  "fechaPublicacion" => "2013-09-01"
  "aid" => "302"
  "copyright" => "Sociedade Portuguesa de Cardiologia"
  "copyrightAnyo" => "2012"
  "documento" => "article"
  "crossmark" => 0
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "ssu"
  "cita" => "Rev Port Cardiol. 2013;32:681-6"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 5179
    "formatos" => array:3 [
      "EPUB" => 160
      "HTML" => 4062
      "PDF" => 957
    ]
  ]
  "Traduccion" => array:1 [
    "pt" => array:20 [
      "pii" => "S0870255113001315"
      "issn" => "08702551"
      "doi" => "10.1016/j.repc.2013.01.006"
      "estado" => "S300"
      "fechaPublicacion" => "2013-09-01"
      "aid" => "302"
      "copyright" => "Sociedade Portuguesa de Cardiologia"
      "documento" => "article"
      "crossmark" => 0
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "ssu"
      "cita" => "Rev Port Cardiol. 2013;32:681-6"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 8750
        "formatos" => array:3 [
          "EPUB" => 172
          "HTML" => 7059
          "PDF" => 1519
        ]
      ]
      "pt" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Artigo de revis&#227;o</span>"
        "titulo" => "A prescri&#231;&#227;o fora das indica&#231;&#245;es aprovadas <span class="elsevierStyleItalic">&#40;off-label&#41;</span>&#58; pr&#225;tica e problemas"
        "tienePdf" => "pt"
        "tieneTextoCompleto" => "pt"
        "tieneResumen" => array:2 [
          0 => "pt"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "681"
            "paginaFinal" => "686"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Off-label prescription&#58; Practice and problems"
          ]
        ]
        "contieneResumen" => array:2 [
          "pt" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "pt" => true
        ]
        "contienePdf" => array:1 [
          "pt" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Ant&#243;nio Vaz Carneiro, Jo&#227;o Costa"
            "autores" => array:2 [
              0 => array:2 [
                "nombre" => "Ant&#243;nio"
                "apellidos" => "Vaz Carneiro"
              ]
              1 => array:2 [
                "nombre" => "Jo&#227;o"
                "apellidos" => "Costa"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "pt"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2174204913001803"
          "doi" => "10.1016/j.repce.2013.01.016"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204913001803?idApp=UINPBA00004E"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255113001315?idApp=UINPBA00004E"
      "url" => "/08702551/0000003200000009/v1_201309260109/S0870255113001315/v1_201309260109/pt/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2174204913002468"
    "issn" => "21742049"
    "doi" => "10.1016/j.repce.2013.02.016"
    "estado" => "S300"
    "fechaPublicacion" => "2013-09-01"
    "aid" => "313"
    "copyright" => "Sociedade Portuguesa de Cardiologia"
    "documento" => "article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "ssu"
    "cita" => "Rev Port Cardiol. 2013;32:687-700"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3948
      "formatos" => array:3 [
        "EPUB" => 184
        "HTML" => 3194
        "PDF" => 570
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>"
      "titulo" => "Heart rate variability in myocardial infarction patients&#58; Effects of exercise training"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "pt"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "687"
          "paginaFinal" => "700"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "pt" => array:1 [
          "titulo" => "Variabilidade da frequ&#234;ncia card&#237;aca em pacientes ap&#243;s enfarte do mioc&#225;rdio&#58; efeitos do exerc&#237;cio f&#237;sico regular"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "pt" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "N&#243;rton Lu&#237;s Oliveira, Fernando Ribeiro, Alberto Jorge Alves, Madalena Teixeira, F&#225;tima Miranda, Jos&#233; Oliveira"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "N&#243;rton Lu&#237;s"
              "apellidos" => "Oliveira"
            ]
            1 => array:2 [
              "nombre" => "Fernando"
              "apellidos" => "Ribeiro"
            ]
            2 => array:2 [
              "nombre" => "Alberto Jorge"
              "apellidos" => "Alves"
            ]
            3 => array:2 [
              "nombre" => "Madalena"
              "apellidos" => "Teixeira"
            ]
            4 => array:2 [
              "nombre" => "F&#225;tima"
              "apellidos" => "Miranda"
            ]
            5 => array:2 [
              "nombre" => "Jos&#233;"
              "apellidos" => "Oliveira"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204913002468?idApp=UINPBA00004E"
    "url" => "/21742049/0000003200000009/v1_201312060118/S2174204913002468/v1_201312060118/en/main.assets"
  ]
  "itemAnterior" => array:20 [
    "pii" => "S2174204913001785"
    "issn" => "21742049"
    "doi" => "10.1016/j.repce.2013.10.014"
    "estado" => "S300"
    "fechaPublicacion" => "2013-09-01"
    "aid" => "271"
    "copyright" => "Sociedade Portuguesa de Cardiologia"
    "documento" => "article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "Rev Port Cardiol. 2013;32:673-80"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3907
      "formatos" => array:3 [
        "EPUB" => 180
        "HTML" => 2987
        "PDF" => 740
      ]
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "Acute myocardial infarction complicated by cardiogenic shock&#58; What changed over a 10-year time span"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "pt"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "673"
          "paginaFinal" => "680"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "pt" => array:1 [
          "titulo" => "Choque cardiog&#233;nico no enfarte agudo do mioc&#225;rdio&#58; o que mudou nos &#250;ltimos 10 anos&#63;"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "pt" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1739
              "Ancho" => 1570
              "Tamanyo" => 108976
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Kaplan-Meier analysis of all-cause mortality at six months&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "H&#233;lder Dores, Jorge Ferreira, Francisco Costa, Carlos Aguiar, Gon&#231;alo Cardoso, Rui Teles, Pedro de Ara&#250;jo Gon&#231;alves, Lu&#237;s Raposo, Marisa Trabulo, Manuel de Sousa Almeida, Jos&#233; Pedro Neves, Miguel Mendes"
          "autores" => array:12 [
            0 => array:2 [
              "nombre" => "H&#233;lder"
              "apellidos" => "Dores"
            ]
            1 => array:2 [
              "nombre" => "Jorge"
              "apellidos" => "Ferreira"
            ]
            2 => array:2 [
              "nombre" => "Francisco"
              "apellidos" => "Costa"
            ]
            3 => array:2 [
              "nombre" => "Carlos"
              "apellidos" => "Aguiar"
            ]
            4 => array:2 [
              "nombre" => "Gon&#231;alo"
              "apellidos" => "Cardoso"
            ]
            5 => array:2 [
              "nombre" => "Rui"
              "apellidos" => "Teles"
            ]
            6 => array:2 [
              "nombre" => "Pedro de Ara&#250;jo"
              "apellidos" => "Gon&#231;alves"
            ]
            7 => array:2 [
              "nombre" => "Lu&#237;s"
              "apellidos" => "Raposo"
            ]
            8 => array:2 [
              "nombre" => "Marisa"
              "apellidos" => "Trabulo"
            ]
            9 => array:2 [
              "nombre" => "Manuel"
              "apellidos" => "de Sousa Almeida"
            ]
            10 => array:2 [
              "nombre" => "Jos&#233; Pedro"
              "apellidos" => "Neves"
            ]
            11 => array:2 [
              "nombre" => "Miguel"
              "apellidos" => "Mendes"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "pt" => array:9 [
        "pii" => "S0870255113000711"
        "doi" => "10.1016/j.repc.2012.12.013"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "pt"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255113000711?idApp=UINPBA00004E"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204913001785?idApp=UINPBA00004E"
    "url" => "/21742049/0000003200000009/v1_201312060118/S2174204913001785/v1_201312060118/en/main.assets"
  ]
  "en" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>"
    "titulo" => "Off-label prescription&#58; Practice and problems"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "681"
        "paginaFinal" => "686"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Ant&#243;nio Vaz Carneiro, Jo&#227;o Costa"
        "autores" => array:2 [
          0 => array:4 [
            "nombre" => "Ant&#243;nio"
            "apellidos" => "Vaz Carneiro"
            "email" => array:1 [
              0 => "avc&#64;fm&#46;ul&#46;pt"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">¿</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:2 [
            "nombre" => "Jo&#227;o"
            "apellidos" => "Costa"
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Centro de Estudos de Medicina Baseada na Evid&#234;ncia&#44; Faculdade de Medicina&#44; Universidade de Lisboa&#44; Lisboa&#44; Portugal"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "pt" => array:1 [
        "titulo" => "A prescri&#231;&#227;o fora das indica&#231;&#245;es aprovadas <span class="elsevierStyleItalic">&#40;off-label&#41;</span>&#58; pr&#225;tica e problemas"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">A drug is only used in clinical practice after a complex process of research and development that lasts on average 12-15 years&#44; of which marketing authorization is the penultimate step&#46; This is granted by the European Medicines Agency for all European countries&#46; For such authorization to be given&#44; evidence must be provided of efficacy and safety through submission of the results of phase 3 randomized controlled trials &#40;RCTs&#41;&#44; in which the new molecule is compared with placebo or an active comparator&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">In most cases&#44; the last step in the process is the adoption of the drug by national authorities for outpatient and&#47;or hospital use&#46; It is this step that&#44; with rare exceptions&#44; makes the drug available to patients&#46; This decision is taken when the national authority &#40;Infarmed in Portugal&#41; makes a positive appraisal of the new drug&#39;s health and&#47;or economic benefits &#40;the latter through economic evaluation studies&#41;&#44; compared to the alternative reference therapy used in clinical indications for the disease in question&#46; Only if the new drug constitutes a therapeutic innovation &#8211; by filling a therapeutic gap when compared with placebo&#44; no treatment or best supportive care &#8211; will it be adopted&#46; A substance is not necessarily a therapeutic innovation simply because it is new&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Central to this process is the definition of indications for the drug in question&#46; These indications are crucial&#44; because drugs are approved &#40;or not&#41; on the basis of their net clinical benefit for specific and well-defined diseases and &#8211; importantly &#8211; only for these&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Once the drug is granted marketing authorization&#44; the manufacturer can only market it for the approved indication&#40;s&#41;&#59; it is illegal to promote&#44; directly or indirectly&#44; or even to suggest&#44; its use for other diseases or other types of patients &#40;although this does happen<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a>&#41;&#46; Pharmaceutical companies can add new indications to those already approved&#44; but they rarely do&#44; because the clinical trials required are lengthy and expensive and there is little incentive to conduct them&#44; since the drug is already on the market&#46; More common are extensions to the approved indications&#44; such as to other age-groups or to different patient subtypes&#46; Generic drug manufacturers are likewise reluctant to conduct the RCTs needed for new approvals&#44; for the same financial reasons&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">Once the drug is available for use in tens or hundreds of thousands of patients&#44; physicians may realize that some medications can be effective in diseases for which they were not approved&#44; i&#46;e&#46;&#44; no studies have been presented to the regulatory authorities&#44; and therefore they are not formally approved for those indications&#46; Convinced of the benefits for their patients&#44; some physicians prescribe them for unapproved indications &#8211; off-label prescription&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Off-label prescription is thus defined as prescription for an indication&#44; disease&#44; or patient outside the approved indications&#44; or for populations that have not been studied &#40;such as pediatric patients&#41;&#44; or using methods of administration or dosages that have not been approved&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> The rationale for off-label prescription is that the official agencies do not regulate the practice of medicine&#44; and that physicians are free to decide what they consider best for their patients&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">There are two types of off-label prescription&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">&#8226;</span><p id="par0040" class="elsevierStylePara elsevierViewall">the use of a drug that is indicated for a particular disease in a completely different condition&#44; such as anti-epileptic agents for neuropathic pain&#59;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">&#8226;</span><p id="par0045" class="elsevierStylePara elsevierViewall">the use of a drug within its indications&#44; but outside the approved specifications&#44; such as sildenafil&#44; approved for erectile dysfunction but used by patients without this condition in order to enhance sexual performance&#46;</p></li></ul></p><p id="par0050" class="elsevierStylePara elsevierViewall">The spectrum of off-label use includes guideline-recommended practice &#40;aspirin in diabetes for prophylaxis against cardiovascular disease&#41;&#44; last-resort therapy &#40;tacrolimus for autoimmune diseases&#44; in addition to transplantation&#41;&#44; and first-line therapy &#40;gabapentin for painful diabetic neuropathy&#41;&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">Certain types of off-label prescription are of particular concern and require careful scrutiny<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a>&#58;<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">&#8226;</span><p id="par0060" class="elsevierStylePara elsevierViewall">The off-label use of recently introduced drugs is a major problem&#44; since not only will there be virtually no evidence of their benefit&#44; but safety data from pharmacovigilance will also be scarce&#44; obviously complicating their use&#46;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">&#8226;</span><p id="par0065" class="elsevierStylePara elsevierViewall">Novel off-label use &#8211; one that is different from usual clinical practice &#8211; has similar problems of lack of data on efficacy and especially on safety&#44; even if the drug itself has been on the market for more than 3-5 years&#46;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">&#8226;</span><p id="par0070" class="elsevierStylePara elsevierViewall">When any drug with known serious or frequent adverse effects is prescribed off-label&#44; this use merits close attention owing to concerns for patient safety&#46;</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">&#8226;</span><p id="par0075" class="elsevierStylePara elsevierViewall">Finally&#44; off-label prescription of high-cost drugs raises its own questions&#44; since the financial penalty involved demands particular practical reflection&#46;</p></li></ul></p><p id="par0080" class="elsevierStylePara elsevierViewall">In this paper we discuss some formal and practical aspects of off-label prescription&#44; including its prevalence&#44; advantages and disadvantages&#44; and examine the nature of the evidence supporting its use&#46;</p><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">The prevalence of off-label prescription</span><p id="par0085" class="elsevierStylePara elsevierViewall">So long as drugs prescribed off-label are safe&#44; well tolerated and inexpensive&#44; the practice does not usually lead to major problems&#46; However&#44; as stated above&#44; problems arise with high-cost drugs for specific diseases&#44; a well-known example of which is new biological drugs for the treatment of cancer&#59; in some studies&#44; off-label administration of these drugs reaches 75&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">In any event&#44; whether for outpatient or in-hospital use&#44; off-label prescription occurs for almost all drug classes&#44; with a particularly high prevalence for certain drugs &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0095" class="elsevierStylePara elsevierViewall">In cardiology&#44; a typical example of off-label prescription is the use of new anticoagulants &#8211; dabigatran&#44; rivaroxaban&#44; apixaban &#8211; in situations in which warfarin is the first-line drug&#46; A recent analysis examined other off-label uses of cardiological drugs&#44; including thrombin and factor Xa inhibitors<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a>&#59; other common examples are the use of aspirin for cardiological prevention in diabetic patients and of beta-blockers for essential tremor&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">For some drugs&#44; of course&#44; good evidence is available for their use in particular conditions &#40;such as beta-blockers for essential tremor&#44; as mentioned above<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a>&#41; but no formal indication has been approved&#59; it should be borne in mind that only the holder of the marketing authorization has the legal right to alter or add to a drug&#39;s indications&#44; and that the authorities cannot do so&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">One well-publicized case of the existence of evidence for an unapproved indication is of bevacizumab &#40;Avastin&#174;&#41; for age-related macular degeneration&#44; for which the only drug with formal indication is ranibizumab &#40;Lucentis&#174;&#41;&#46; A non-inferiority clinical trial comparing the two&#44; the CATT trial&#44;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> concluded that ranibizumab and bevacizumab had equivalent effects on visual acuity at one year and that differences in rates of serious adverse events require further study&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">Another example of off-label prescription is the use of recombinant factor VIIa&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> Initially approved only for the treatment of hemophilia&#44; especially in patients who have developed factor VII inhibitors&#44; recombinant factor VIIa is used as a hemostatic agent in cardiac surgery&#44; trauma and intracranial hemorrhage&#44; to the point that prescription for approved indications accounts for only 3&#37; of cases&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">The prevalence of off-label prescription has not received the attention that it warrants&#46; Various numbers appear in the literature&#44; ranging from 20&#37;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> to 50&#37; &#40;Pharmaceutical Executive 2012&#41; of prescriptions in the US&#44; 60&#37; in some Australian hospitals &#40;Discussion Paper Working Group of NSW TAG&#44; 2003&#41;&#44; 30&#37; in outpatients in the UK &#40;NICE 2012&#41; and 23&#37; in Europe&#46;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> The most frequently cited study&#44;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> based on a US survey of outpatient prescriptions&#44; reports an overall rate of 21&#37; of off-label prescription&#44; rising to 46&#37; of cardiac medications &#40;excluding lipid-lowering and antihypertensive medications&#41; and of anticonvulsants&#46; Gabapentin had the highest proportion of off-label prescription &#40;83&#37;&#41;&#44; followed by amitriptyline &#40;81&#37;&#41;&#46; In most cases &#40;73&#37;&#41; there was no evidence to back up the use of these drugs outside their approved indications&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">To summarize&#44; off-label prescription is very common&#44; and the drug classes involved are generally the more complex ones&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">The advantages of off-label prescription</span><p id="par0125" class="elsevierStylePara elsevierViewall">Off-label prescription may occur for a variety of different reasons<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a>&#58;<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">1&#46;</span><p id="par0130" class="elsevierStylePara elsevierViewall">a class effect&#44; by which drugs of the same class are presumed have similar effects in a particular disease &#40;for example&#44; the use of a statin for primary prevention that has only been studied for secondary prevention&#41;&#59;</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">2&#46;</span><p id="par0135" class="elsevierStylePara elsevierViewall">extension of therapies approved for severe clinical situations to milder forms&#44; such as the use of spironolactone&#44; approved for patients in NYHA classes III and IV&#44; for patients in classes I and II<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14&#44;15</span></a>&#59;</p></li><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">3&#46;</span><p id="par0140" class="elsevierStylePara elsevierViewall">extension to related conditions &#40;use of the antiasthmatic montelukast for chronic obstructive pulmonary disease&#41;&#59;</p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">4&#46;</span><p id="par0145" class="elsevierStylePara elsevierViewall">expansion to distinct conditions sharing a physiological link &#40;use of the antidiabetic drug metformin to treat polycystic ovarian syndrome&#41;&#59; and</p></li><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">5&#46;</span><p id="par0150" class="elsevierStylePara elsevierViewall">extension to conditions whose symptoms overlap with those of an approved indication&#44; in the belief that the off-label treatment will be equally effective &#40;gabapentin for non-neuropathic pain syndromes&#41;&#46;</p></li></ul></p><p id="par0155" class="elsevierStylePara elsevierViewall">Besides these justifications for off-label prescription&#44; there are other arguments in its favor<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6&#44;11</span></a>&#58; it enables new indications to be discovered&#44; particularly when approved treatments have failed&#59; it can dispense with the lengthy and costly drug approval process via official agencies&#44; offering earlier access to drugs and adoption of new practices based on emerging evidence &#40;and thereby enabling physicians to accumulate evidence prior to official approval&#41;&#59; and experimentation with new drugs can be justified for many less common diseases for which there are no effective approved treatments&#46;</p><p id="par0160" class="elsevierStylePara elsevierViewall">Furthermore&#44; there are some circumstances in which there is no alternative to off-label prescription&#46; The most obvious example of this is pediatrics&#46; Since very few clinical trials are performed in children&#44; most drugs used in pediatric populations do not have approved indications&#46; Another example is in certain rare diseases that also lack approved treatments due to the impossibility of carrying out effective clinical trials&#59; here also the only possible treatment may be with drugs approved for other conditions&#46; But off-label prescription for common conditions also occurs in clinical practice&#59; for example&#44; the use of beta-blockers in congestive heart failure began before there were clinical trials to support this indication&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Problems with off-label prescription</span><p id="par0165" class="elsevierStylePara elsevierViewall">Given the complex and painstaking process of approval and introduction that new drugs must go through&#44; which is intended to ensure both their efficacy and safety&#44; any use outside the indications for which they were evaluated naturally raises important questions&#46;</p><p id="par0170" class="elsevierStylePara elsevierViewall">Prescription of a drug outside its approved indications will increase the individual physician&#39;s civil and criminal responsibility&#46; It has been suggested that physicians should in some cases be obliged to provide patients with information on the risks of off-label prescription and to obtain their consent &#8211; a similar process to the informed consent process&#46;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> In times of economic constraints other considerations come into play&#44; since health authorities &#8211; whether local &#40;hospitals and family health centers&#41;&#44; regional or national &#8211; are under increasing pressure to audit and monitor drug prescriptions and to take measures&#44; individually and collectively&#44; to rationalize their use&#46;</p><p id="par0175" class="elsevierStylePara elsevierViewall">Unlike physicians&#44; the drug manufacturers have little legal liability with regard to off-label prescription&#44; since they can only be held responsible for problems that arise when their product is used within its approved indications&#46; Furthermore&#44; off-label prescription may in fact discourage the pharmaceutical industry from conducting clinical trials for new or different indications &#40;thereby reducing public confidence in the drug evaluation process&#41;&#44; encourage ever wider use in unstudied populations such as children and the elderly&#44; and&#44; when the drugs in question are expensive&#44; increase health care costs&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">One of the main concerns with off-label prescription is the lack of effective pharmacovigilance due to a low level of reporting&#44; which may obscure safety issues&#46; It should be recalled that drugs with a good safety profile for a specific use&#44; prescribed for the studied population and with the approved indications&#44; may not be safe with unapproved use and&#47;or in unstudied patient groups&#46;</p><p id="par0185" class="elsevierStylePara elsevierViewall">An example of this is the CATT trial referred to above&#44; which compared ranibizumab &#40;the approved drug&#41; and bevacizumab &#40;unapproved&#41; for the treatment of age-related macular degeneration&#44; and which revealed differences in serious adverse effects between the two&#46;<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8&#44;16</span></a> Although the differences did not permit firm conclusions to be drawn&#44; the authors stated that further studies were required to assess the safety of the two drugs&#44; particularly bevacizumab&#46; This led to a recent systematic review directly comparing three RCTs&#44; including the CATT trial&#44; with a total of 1333 patients&#44; that assessed the safety of off-label use of bevacizumab vs&#46; ranibizumab for the same indications&#46;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> The results showed that bevacizumab has a significantly higher rate of ocular adverse effects &#40;risk ratio &#91;RR&#93; 2&#46;8&#59; 95&#37; confidence interval &#91;CI&#93; 1&#46;2-6&#46;5&#41; and serious infections and gastrointestinal disorders &#40;RR 1&#46;3&#59; 95&#37; CI 1&#46;0-1&#46;7&#41;&#46; In indirect comparisons with a variety of controls &#40;5 RCTs&#44; 4054 patients&#41;&#44; and based on the two-year results of three landmark trials&#44; the risk of ocular adverse effects was higher for bevacizumab &#40;RR 3&#46;1&#59; 95&#37; CI 1&#46;1-8&#46;9&#41;&#44; even though the absolute baseline risk for these patients was low &#40;2&#46;1&#37;&#41;&#46; A significant increase in nonocular hemorrhage was observed with ranibizumab &#40;RR 1&#46;7&#59; 95&#37; CI 1&#46;1-2&#46;7&#41;&#44; while no difference was detected in the incidence of arterial thromboembolic events&#46;</p><p id="par0190" class="elsevierStylePara elsevierViewall">As well as providing a better characterization of the safety of off-label bevacizumab&#44; this review included several studies and was thus better able to find differences between the drugs&#44; thereby partly overcoming the limitations of individual trials to identify safety issues&#46; The consequence in this case has been a change in the Summary of Product Characteristics for bevacizumab&#44; which now include the risk of ocular adverse reactions following unapproved intravitreal use of bevacizumab under the heading &#8220;Special warnings and precautions for use&#8221; &#40;<a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf">http&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;docs&#47;en&#95;GB&#47;document&#95;library&#47;EPAR&#95;-&#95;Product&#95;Information&#47;human&#47;000582&#47;WC500029271&#46;pdf</a>&#44; accessed October 31&#44; 2012&#41;&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">Besides the potential safety issues with off-label bevacizumab&#44; the results of the CATT trial are a classic example of the limited ability of clinical trials to characterize the safety and tolerability of drug therapies&#44; particularly when adverse events are uncommon &#40;though serious&#41; and&#47;or occur late&#44; due to the limited number of patients and duration of the trial&#46; A well-known recent example was the cardiovascular risk of cyclooxygenase inhibitors&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> Most clinical trials now have open extensions&#44; during which patients are treated for a specific period &#40;usually until the new drug is licensed&#41;&#46; The main aim of such extensions is to evaluate safety and tolerability&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">The evidence for off-label prescription</span><p id="par0200" class="elsevierStylePara elsevierViewall">As stated above&#44; the evidence produced by the original investigation is mainly intended for the regulatory approval process of new drugs with a view to their introduction to the market&#46; However&#44; there may be evidence that could serve as the basis for the drug to be used outside its approved indications&#46; In this case&#44; the question is whether the physician can justify off-label prescription if there is good evidence to support the practice&#46;</p><p id="par0205" class="elsevierStylePara elsevierViewall">In our opinion&#44; routine off-label use of drugs may be justified if there is high-quality &#40;real-world&#41; evidence that they are effective and safe&#44; and that their overall risk&#47;benefit ratio is acceptable for a specific context &#40;such as data on long-term use in chronic diseases&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0210" class="elsevierStylePara elsevierViewall">One proposed classification of evidence that could support off-label prescription divides it into supported evidence &#40;with a moderate to high level of certainty of net health benefits&#41;&#44; suppositional evidence &#40;a low level of certainty&#41;&#44; and investigational evidence &#40;unknown level&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0215" class="elsevierStylePara elsevierViewall">One of the more complicated problems with evidence that may support off-label prescription is that it can be presented in a variety of ways&#44; some of which lack rigor&#46; A recent study of compendia of indications for off-label oncology treatments<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> found that they cited little of the available evidence&#44; often neither the most recent nor that of highest methodological quality&#44; and were analyzed on a completely random basis&#46; For the 14 off-label indications studied&#44; the compendia differed in the indications included and whether and how they recommended particular agents for particular types of cancer&#46;</p><p id="par0220" class="elsevierStylePara elsevierViewall">To summarize&#44; off-label use of a drug may be justified if there is high-quality evidence to support such use&#44; bearing in mind that the results may differ markedly from those obtained when the drug is used within its approved indications&#46;</p></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusions</span><p id="par0225" class="elsevierStylePara elsevierViewall">Off-label prescription is an inescapable aspect of modern health care systems&#46;</p><p id="par0230" class="elsevierStylePara elsevierViewall">In this paper we set out to examine the need to obtain evidence to support the use of drugs outside their approved indications and thereby to promote rational and evidence-based prescription&#46; Such use should always be an exception&#44; to reduce inappropriate use and to ensure patients&#8217; safety&#46;</p><p id="par0235" class="elsevierStylePara elsevierViewall">When prescribing&#44; the physician should pay particular attention to the adverse effects of off-label use and whenever possible should obtain supporting evidence&#46;</p><p id="par0240" class="elsevierStylePara elsevierViewall">Although we recognize that in certain areas&#44; such as pediatrics and oncology&#44; off-label prescription is inevitable&#44; we argue that it should always be an exception and should be supported by high-quality evidence that the physician must be able to explain&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Ethical disclosures</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Protection of human and animal subjects</span><p id="par0245" class="elsevierStylePara elsevierViewall">The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association &#40;Declaration of Helsinki&#41;&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Confidentiality of data</span><p id="par0250" class="elsevierStylePara elsevierViewall">The authors declare that they have followed the protocols of their work center on the publication of patient data and that all the patients included in the study received sufficient information and gave their written informed consent to participate in the study&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Right to privacy and informed consent</span><p id="par0255" class="elsevierStylePara elsevierViewall">The authors have obtained the written informed consent of the patients or subjects mentioned in the article&#46; The corresponding author is in possession of this document&#46;</p></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Conflicts of interest</span><p id="par0260" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:9 [
        0 => array:2 [
          "identificador" => "xres296957"
          "titulo" => "Abstract"
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec280622"
          "titulo" => "Keywords"
        ]
        2 => array:2 [
          "identificador" => "xres296956"
          "titulo" => "Resumo"
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec280621"
          "titulo" => "Palavras-chave"
        ]
        4 => array:3 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "sec0010"
              "titulo" => "The prevalence of off-label prescription"
            ]
            1 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "The advantages of off-label prescription"
            ]
            2 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Problems with off-label prescription"
            ]
            3 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "The evidence for off-label prescription"
            ]
          ]
        ]
        5 => array:2 [
          "identificador" => "sec0030"
          "titulo" => "Conclusions"
        ]
        6 => array:3 [
          "identificador" => "sec0035"
          "titulo" => "Ethical disclosures"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Protection of human and animal subjects"
            ]
            1 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Confidentiality of data"
            ]
            2 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Right to privacy and informed consent"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0055"
          "titulo" => "Conflicts of interest"
        ]
        8 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2012-12-22"
    "fechaAceptado" => "2013-01-19"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec280622"
          "palabras" => array:4 [
            0 => "Off-label prescription"
            1 => "Drug efficacy and safety"
            2 => "Drug indications"
            3 => "Drug regulatory approval processes"
          ]
        ]
      ]
      "pt" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palavras-chave"
          "identificador" => "xpalclavsec280621"
          "palabras" => array:4 [
            0 => "Prescri&#231;&#227;o <span class="elsevierStyleItalic">off-label</span>"
            1 => "Efic&#225;cia e seguran&#231;a de medicamentos"
            2 => "Indica&#231;&#245;es medicamentosas"
            3 => "Processos regulamentares de aprova&#231;&#227;o de medicamentos"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Approval of a drug for clinical use requires production of data on efficacy and safety through submission of results from randomized controlled trials &#40;RCTs&#41;&#44; in which the new molecule is usually compared with placebo &#40;or an active comparator&#41; for a set of outcomes that will serve as the basis for the drug&#39;s indications&#46; These indications are crucial&#44; because drugs are approved on the basis of their net clinical benefit for specific and well-defined diseases and&#8211;importantly&#8211;only for these&#46; Once the drug is available for use in tens or hundreds of thousands of patients&#44; physicians may realize that some medications can be effective in diseases for which they were not approved&#44; i&#46;e&#46;&#44; no studies have been presented to the regulatory authorities&#44; and therefore they are not formally approved for those indications&#46; Convinced of the benefits for their patients&#44; some physicians prescribe them for unapproved indications&#8211;off-label prescription&#46;</p>"
      ]
      "pt" => array:2 [
        "titulo" => "Resumo"
        "resumen" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">O processo de aprova&#231;&#227;o de medicamentos para uso cl&#237;nico implica a produ&#231;&#227;o de provas de efic&#225;cia e seguran&#231;a atrav&#233;s da submiss&#227;o de resultados de ensaios cl&#237;nicos&#44; em que a nova mol&#233;cula &#233; comparada habitualmente ao placebo &#40;ou a um comparador ativo&#41; para um conjunto de resultados nos quais se basear&#225; a determina&#231;&#227;o das indica&#231;&#245;es&#46; As indica&#231;&#245;es s&#227;o absolutamente cruciais&#44; porque os f&#225;rmacos s&#227;o aprovados segundo o perfil de benef&#237;cio&#47;risco que apresentam para tratamento de patologias espec&#237;ficas&#44; bem definidas e - um aspeto muito importante - apenas para estas&#46; Uma vez estando o medicamento dispon&#237;vel para ser utilizado em dezenas ou centenas de milhares de doentes&#44; acontece por vezes que&#44; no decurso do seu uso regular e rotineiro&#44; chega ao conhecimento dos m&#233;dicos que certas mol&#233;culas podem ser eficazes em situa&#231;&#245;es para as quais n&#227;o foram aprovadas&#44; isto &#233;&#44; em que n&#227;o foram apresentados estudos de suporte &#224;s autoridades regulamentares e que portanto n&#227;o est&#227;o legalmente aprovadas para essas indica&#231;&#245;es&#46; Convictos dos benef&#237;cios para os seus doentes&#44; alguns m&#233;dicos v&#227;o receitar medicamentos para indica&#231;&#245;es n&#227;o aprovadas - a chamada prescri&#231;&#227;o <span class="elsevierStyleItalic">off-label</span>&#46;</p><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Neste artigo discute-se a preval&#234;ncia da prescri&#231;&#227;o <span class="elsevierStyleItalic">off-label</span>&#44; assim como as suas vantagens e inconvenientes&#46;</p>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Vaz Carneiro A&#44; Costa J&#46; A prescri&#231;&#227;o fora das indica&#231;&#245;es aprovadas <span class="elsevierStyleItalic">&#40;off-label&#41;</span>&#58; pr&#225;tica e problemas&#46; Rev Port Cardiol&#46; 2013&#59;32&#58;681&#8211;686&#46;</p>"
      ]
    ]
    "multimedia" => array:1 [
      0 => array:7 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">ADHD&#58; attention deficit&#47;hyperactivity disorder&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Type of drug&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Examples of off-label use&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti-seizure drugs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Migraines&#44; depression&#44; nerve pain&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antipsychotics&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alzheimer&#39;s disease&#44; autism&#44; dementia&#44; ADHD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antidepressants&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Chronic pain&#44; ADHD&#44; bipolar disorder&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antihistamines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Colds&#44; asthma&#44; ear infection symptoms&#44; as sleep aids&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antibiotics&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Viral infections &#40;colds and influenza&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anxiety drugs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">To ease &#8220;normal&#8221; life stresses&#44; as sleep aids&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Proton pump inhibitors&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Occasional heartburn&#44; indigestion&#44; irritable bowel&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Beta-blockers&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Migraine&#44; heart rhythm disorders&#44; anxiety&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Drugs to treat ADHD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">For people not diagnosed with ADHD&#44; to enhance alertness and concentration&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Insomnia medicines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">For people with infrequent insomnia&#44; insomnia associated with depression&#44; anxiety&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Narcotic pain relievers&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">For people with only mild&#44; infrequent pain&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Specific drugs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Examples of off-label use&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Aripiprazole &#40;antipsychotic&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dementia&#44; Alzheimer&#39;s disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Albuterol &#40;for asthma&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bad coughs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Lamictal &#40;antiepileptic&#44; anti-seizure&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Depression&#44; bipolar disorder&#44; mood stabilization&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tiagabine &#40;antiepileptic&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Depression&#44; mood stabilization&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Gabapentin &#40;antiepileptic&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Depression&#44; nerve pain&#44; migraines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Topiramate &#40;antiepileptic&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Migraines&#44; bipolar disorder&#44; depression&#44; nerve pain&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Risperidone &#40;antipsychotic&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alzheimer&#39;s disease&#44; dementia&#44; eating disorders&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Lidoderm &#40;skin patch for shingles&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Lower back pain&#44; sore muscles&#44; tennis elbow&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Trazodone &#40;antidepressant&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">As a sleep aid and for insomnia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Propranolol &#40;high blood pressure and heart disease&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Performance anxiety&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Modafinil &#40;for excessive sleepiness&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">To enhance wakefulness and alertness&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sildenafil&#44; vardenafil&#44; tadalafil &#40;erectile dysfunction&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">To enhance sexual performance in people not diagnosed with erectile dysfunction&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bevacizumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Wet age-related macular degeneration&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab433149.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Drugs commonly prescribed off-label &#40;Consumer Reports Best Buy Drugs&#44; <span class="elsevierStyleInterRef" id="intr0005" href="http://www.crbestbuydrugs.org/">www&#46;CRBestBuyDrugs&#46;org</span>&#44; accessed August 2012&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a></p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:20 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Valor terap&#234;utico acrescentado"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "C&#46; Ribeiro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rev Port Clin Geral"
                        "fecha" => "2008"
                        "volumen" => "24"
                        "paginaInicial" => "723"
                        "paginaFinal" => "728"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A hemorrhage of off-label use"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "J&#46; Avorn"
                            1 => "A&#46; Kesselheim"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7326/0003-4819-154-8-201104190-00010"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Intern Med"
                        "fecha" => "2011"
                        "volumen" => "154"
                        "paginaInicial" => "566"
                        "paginaFinal" => "567"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21502655"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Off-label use of medicines&#58; Consensus recommendations for evaluating appropriateness"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "M&#46; Gazarian"
                            1 => "M&#46; Kelly"
                            2 => "J&#46;R&#46; McPhee"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Med J Aust"
                        "fecha" => "2006"
                        "volumen" => "185"
                        "paginaInicial" => "544"
                        "paginaFinal" => "548"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17115966"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Going off-label without venturing off-course&#58; Evidence and ethical off-label prescribing"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "E&#46;A&#46; Largent"
                            1 => "F&#46;G&#46; Miller"
                            2 => "S&#46;D&#46; Pearson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/archinternmed.2009.314"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Intern Med"
                        "fecha" => "2009"
                        "volumen" => "169"
                        "paginaInicial" => "1745"
                        "paginaFinal" => "1747"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19858430"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of off-label use of oncology drugs on pharmaceutical costs&#58; The rituximab experience"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "D&#46; Kocs"
                            1 => "A&#46;M&#46; Fendrick"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Manag Care"
                        "fecha" => "2003"
                        "volumen" => "9"
                        "paginaInicial" => "393"
                        "paginaFinal" => "400"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12744301"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Regulating off-label drug use--rethinking the role of the FDA"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "R&#46;S&#46; Stafford"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMp0802107"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2008"
                        "volumen" => "358"
                        "paginaInicial" => "1427"
                        "paginaFinal" => "1429"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18385495"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Essential tremor"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "J&#46;J&#46; Ferreira"
                            1 => "S&#46; Sampaio"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Clin Evidence"
                        "fecha" => "2007"
                        "paginaInicial" => "1206"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ranibizumab and bevacizumab for neovascular age-related macular degeneration"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "D&#46;F&#46; Martin"
                            1 => "M&#46;G&#46; Maguire"
                            2 => "G&#46;S&#46; Ying"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1102673"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2011"
                        "volumen" => "364"
                        "paginaInicial" => "1897"
                        "paginaFinal" => "1908"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21526923"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Off-label use of recombinant factor VIIa in U&#46;S&#46; hospitals&#58; Analysis of hospital records"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46;C&#46; Logan"
                            1 => "V&#46; Yank"
                            2 => "R&#46;S&#46; Stafford"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7326/0003-4819-154-8-201104190-00002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Int Med"
                        "fecha" => "2011"
                        "volumen" => "154"
                        "paginaInicial" => "516"
                        "paginaFinal" => "522"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21502649"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systematic review&#58; Benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "V&#46; Yank"
                            1 => "C&#46;V&#46; Tuohy"
                            2 => "A&#46;C&#46; Logan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7326/0003-4819-154-8-201104190-00004"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Int Med"
                        "fecha" => "2011"
                        "volumen" => "154"
                        "paginaInicial" => "529"
                        "paginaFinal" => "540"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21502651"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Controlling off-label medication use"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "M&#46;R&#46; Gillick"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Int Med"
                        "fecha" => "2009"
                        "volumen" => "150"
                        "paginaInicial" => "344"
                        "paginaFinal" => "347"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19221367"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prescri&#231;&#227;o de medicamentos off-label"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "A&#46; Escoval"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rev Port Farmacoter"
                        "fecha" => "2011"
                        "volumen" => "3"
                        "paginaInicial" => "169"
                        "paginaFinal" => "171"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Off-label prescribing among office-based physicians"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "D&#46;C&#46; Radley"
                            1 => "S&#46;N&#46; Finkelstein"
                            2 => "R&#46;S&#46; Stafford"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/archinte.166.9.1021"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Intern Med"
                        "fecha" => "2006"
                        "volumen" => "166"
                        "paginaInicial" => "1021"
                        "paginaFinal" => "1026"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16682577"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "D&#46;N&#46; Juurlink"
                            1 => "M&#46;M&#46; Mamdani"
                            2 => "D&#46;S&#46; Lee"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa040135"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2004"
                        "volumen" => "351"
                        "paginaInicial" => "543"
                        "paginaFinal" => "551"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15295047"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of heart failure with spironolactone-trial and tribulations"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "J&#46;J&#46; McMurray"
                            1 => "E&#46; O&#8217;Meara"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMp048144"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2004"
                        "volumen" => "351"
                        "paginaInicial" => "526"
                        "paginaFinal" => "528"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15295043"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bevacizumab versus ranibizumab for AMD"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "P&#46;J&#46; Rosenfeld"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMe1103334"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2011"
                        "volumen" => "364"
                        "paginaInicial" => "1966"
                        "paginaFinal" => "1967"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21526924"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A safety review and meta-analyses of bevacizumab and ranibizumab&#58; Off-label versus goldstandard"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "C&#46; Schmucker"
                            1 => "C&#46; Ehlken"
                            2 => "H&#46;T&#46; Agostini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pone.0042701"
                      "Revista" => array:5 [
                        "tituloSerie" => "PLoS One"
                        "fecha" => "2012"
                        "volumen" => "7"
                        "paginaInicial" => "e42701"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22880086"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical trials in the wake of Vioxx&#58; Requiring statistically extreme evidence of benefit to ensure the safety of new drugs"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "M&#46;D&#46; Roth-Cline"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1161/CIRCULATIONAHA.105.604512"
                      "Revista" => array:6 [
                        "tituloSerie" => "Circulation"
                        "fecha" => "2006"
                        "volumen" => "113"
                        "paginaInicial" => "2253"
                        "paginaFinal" => "2259"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16684875"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systematic review&#58; Reliability of compendia methods for off-label oncology indications"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "A&#46;P&#46; Abernethy"
                            1 => "G&#46; Raman"
                            2 => "E&#46;M&#46; Balk"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Int Med"
                        "fecha" => "2009"
                        "volumen" => "150"
                        "paginaInicial" => "336"
                        "paginaFinal" => "343"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19221366"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Consumer Reports Best Buy Drugs &#91;accessed 10 August 2012&#93;&#46; Available from&#58; <a id="intr0020" class="elsevierStyleInterRef" href="http://www.crbestbuydrugs.org/">www&#46;CRBestBuyDrugs&#46;org</a>&#46;"
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/21742049/0000003200000009/v1_201312060118/S2174204913001803/v1_201312060118/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "21467"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Evidenced-Based Cardiology"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/21742049/0000003200000009/v1_201312060118/S2174204913001803/v1_201312060118/en/main.pdf?idApp=UINPBA00004E&text.app=https://revportcardiol.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204913001803?idApp=UINPBA00004E"
]

Article information

ISSN: 21742049
Original language: English

DOI:10.1016/j.repce.2013.01.016

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	9	6	15
2024 October	87	33	120
2024 September	113	36	149
2024 August	77	34	111
2024 July	56	31	87
2024 June	54	21	75
2024 May	96	26	122
2024 April	44	33	77
2024 March	52	20	72
2024 February	55	24	79
2024 January	69	31	100
2023 December	54	23	77
2023 November	55	31	86
2023 October	60	17	77
2023 September	66	29	95
2023 August	48	24	72
2023 July	52	9	61
2023 June	47	12	59
2023 May	77	43	120
2023 April	69	6	75
2023 March	116	30	146
2023 February	90	24	114
2023 January	68	31	99
2022 December	79	27	106
2022 November	91	20	111
2022 October	100	30	130
2022 September	120	27	147
2022 August	78	36	114
2022 July	50	34	84
2022 June	47	24	71
2022 May	45	31	76
2022 April	48	20	68
2022 March	51	27	78
2022 February	35	13	48
2022 January	38	20	58
2021 December	33	24	57
2021 November	50	40	90
2021 October	62	41	103
2021 September	41	25	66
2021 August	41	24	65
2021 July	26	27	53
2021 June	32	18	50
2021 May	39	44	83
2021 April	137	64	201
2021 March	113	22	135
2021 February	112	17	129
2021 January	63	17	80
2020 December	51	7	58
2020 November	45	14	59
2020 October	21	6	27
2020 September	56	11	67
2020 August	20	6	26
2020 July	42	6	48
2020 June	52	8	60
2020 May	31	6	37
2020 April	33	8	41
2020 March	39	6	45
2020 February	40	15	55
2020 January	28	6	34
2019 December	28	6	34
2019 November	17	6	23
2019 October	31	3	34
2019 September	19	13	32
2019 August	26	3	29
2019 July	34	10	44
2019 June	20	8	28
2019 May	54	10	64
2019 April	31	16	47
2019 March	85	13	98
2019 February	88	10	98
2019 January	45	5	50
2018 December	45	10	55
2018 November	93	7	100
2018 October	136	16	152
2018 September	38	15	53
2018 August	32	8	40
2018 July	31	7	38
2018 June	25	10	35
2018 May	55	9	64
2018 April	20	4	24
2018 March	51	9	60
2018 February	39	11	50
2018 January	41	29	70
2017 December	70	4	74
2017 November	47	14	61
2017 October	55	15	70
2017 September	44	6	50
2017 August	37	15	52
2017 July	35	9	44
2017 June	60	19	79
2017 May	45	13	58
2017 April	35	4	39
2017 March	34	40	74
2017 February	33	2	35
2017 January	30	4	34
2016 December	43	15	58
2016 November	31	12	43
2016 October	42	12	54
2016 September	25	17	42
2016 August	7	1	8
2016 July	21	13	34
2016 June	21	11	32
2016 May	21	6	27
2016 April	51	2	53
2016 March	130	34	164
2016 February	120	42	162
2016 January	90	19	109
2015 December	159	20	179
2015 November	89	14	103
2015 October	103	25	128
2015 September	83	14	97
2015 August	81	14	95
2015 July	75	17	92
2015 June	31	5	36
2015 May	73	14	87
2015 April	88	22	110
2015 March	45	7	52
2015 February	59	4	63
2015 January	44	14	58
2014 December	75	17	92
2014 November	84	9	93
2014 October	92	15	107
2014 September	76	7	83
2014 August	78	14	92
2014 July	58	14	72
2014 June	44	9	53
2014 May	73	17	90
2014 April	46	9	55
2014 March	66	23	89
2014 February	67	28	95
2014 January	62	23	85
2013 December	40	17	57

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter